132 related articles for article (PubMed ID: 23663197)
1. Responses to Medicare drug costs among near-poor versus subsidized beneficiaries.
Fung V; Reed M; Price M; Brand R; Dow WH; Newhouse JP; Hsu J
Health Serv Res; 2013 Oct; 48(5):1653-68. PubMed ID: 23663197
[TBL] [Abstract][Full Text] [Related]
2. Consequences of forgoing prescription drug subsidies among low-income Medicare beneficiaries with diabetes.
Glynn A; Hernandez I; Roberts ET
Health Serv Res; 2022 Oct; 57(5):1136-1144. PubMed ID: 35430735
[TBL] [Abstract][Full Text] [Related]
3. How Low-Income Subsidy Recipients Respond to Medicare Part D Cost Sharing.
Stuart B; Hendrick FB; Xu J; Dougherty JS
Health Serv Res; 2017 Jun; 52(3):1185-1206. PubMed ID: 27324201
[TBL] [Abstract][Full Text] [Related]
4. Medicare beneficiaries' knowledge of Part D prescription drug program benefits and responses to drug costs.
Hsu J; Fung V; Price M; Huang J; Brand R; Hui R; Fireman B; Newhouse JP
JAMA; 2008 Apr; 299(16):1929-36. PubMed ID: 18430912
[TBL] [Abstract][Full Text] [Related]
5. Cognition and take-up of subsidized drug benefits by Medicare beneficiaries.
Kuye IO; Frank RG; McWilliams JM
JAMA Intern Med; 2013 Jun; 173(12):1100-7. PubMed ID: 23649604
[TBL] [Abstract][Full Text] [Related]
6. Medicare Part D low-income subsidies expanded in January 2024, but more needs to be done to ensure that eligible beneficiaries enroll.
Loh FE; Stuart BC; Hunt RJ; Negari M
J Manag Care Spec Pharm; 2024 Mar; 30(3):279-289. PubMed ID: 38324387
[TBL] [Abstract][Full Text] [Related]
7. The relationship between the low-income subsidy and cost-related nonadherence to drug therapies in Medicare Part D.
Wei II; Lloyd JT; Shrank WH
J Am Geriatr Soc; 2013 Aug; 61(8):1315-23. PubMed ID: 23889465
[TBL] [Abstract][Full Text] [Related]
8. Subsidies for Oral Chemotherapy and Use of Immunomodulatory Drugs Among Medicare Beneficiaries With Myeloma.
Olszewski AJ; Dusetzina SB; Eaton CB; Davidoff AJ; Trivedi AN
J Clin Oncol; 2017 Oct; 35(29):3306-3314. PubMed ID: 28541791
[TBL] [Abstract][Full Text] [Related]
9. Potential savings associated with drug substitution in Medicare Part D: the Translating Research into Action for Diabetes (TRIAD) study.
Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF; Fu J; Simien L; Tseng CW
J Gen Intern Med; 2014 Jan; 29(1):230-6. PubMed ID: 23975059
[TBL] [Abstract][Full Text] [Related]
10. Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.
Li P; Wong YN; Jahnke J; Pettit AR; Doshi JA
Cancer Med; 2018 Jan; 7(1):75-86. PubMed ID: 29195016
[TBL] [Abstract][Full Text] [Related]
11. Associations Between Annual Medicare Part D Low-Income Subsidy Loss and Prescription Drug Spending and Use.
Fung V; Price M; Cheng D; Patel TA; Yang Z; Hsu J; Alegria M; Newhouse JP
JAMA Health Forum; 2024 Feb; 5(2):e235152. PubMed ID: 38306091
[TBL] [Abstract][Full Text] [Related]
12. The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis.
Hartung DM; Johnston KA; McGregor JC; Bourdette DN
Mult Scler Relat Disord; 2020 Nov; 46():102554. PubMed ID: 33032059
[TBL] [Abstract][Full Text] [Related]
13. Patterns of prescription drug expenditures and medication adherence among medicare part D beneficiaries with and without the low-income supplement.
Yala SM; Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF
BMC Health Serv Res; 2014 Dec; 14():665. PubMed ID: 25526892
[TBL] [Abstract][Full Text] [Related]
14. Variation in Prescription Drug Coverage Enrollment Among Vulnerable Beneficiaries With Glaucoma Before and After the Implementation of Medicare Part D.
Blumberg DM; Prager AJ; Liebmann JM
JAMA Ophthalmol; 2016 Feb; 134(2):212-20. PubMed ID: 26720853
[TBL] [Abstract][Full Text] [Related]
15. Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2015 Oct; 21(10):956-64. PubMed ID: 26402394
[TBL] [Abstract][Full Text] [Related]
16. Sociodemographic and spending characteristics of Medicare beneficiaries taking prescription drugs subject to price negotiations.
Odouard IC; Anderson GF; Alexander GC; Ballreich J
J Manag Care Spec Pharm; 2024 Mar; 30(3):269-278. PubMed ID: 38140901
[TBL] [Abstract][Full Text] [Related]
17. Specialty Tier-Level Cost Sharing and Biologic Agent Use in the Medicare Part D Initial Coverage Period Among Beneficiaries With Rheumatoid Arthritis.
Doshi JA; Hu T; Li P; Pettit AR; Yu X; Blum M
Arthritis Care Res (Hoboken); 2016 Nov; 68(11):1624-1630. PubMed ID: 27014854
[TBL] [Abstract][Full Text] [Related]
18. Impact of Part D low-income subsidies on medication patterns for Medicare beneficiaries with diabetes.
Stuart B; Yin X; Davidoff A; Simoni-Wastila L; Zuckerman I; Shoemaker JS; Doshi J
Med Care; 2012 Nov; 50(11):913-9. PubMed ID: 23047779
[TBL] [Abstract][Full Text] [Related]
19. The Effects of Cost Sharing on Adherence to Medications Prescribed for Concurrent Use: Do Definitions Matter?
Sacks NC; Burgess JF; Cabral HJ; McDonnell ME; Pizer SD
J Manag Care Spec Pharm; 2015 Aug; 21(8):678-87. PubMed ID: 26233540
[TBL] [Abstract][Full Text] [Related]
20. Minimizing out-of-pocket prescription drug costs for Medicare beneficiaries: not just 'a drop in the bucket'.
Patel RA; Vo KA; Chu T; Wang K; Lu S; Woelfel JA; Carr-Lopez SM; Galal SM
J Am Pharm Assoc (2003); 2014; 54(6):604-9. PubMed ID: 25379981
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
